



To:

THE DIRECTOR GENERAL OF HEALTH SERVICES IN ALL GOVERNORATES

Commanding Officer, Armed Forces Hospital (Al Khoudh & Salalah)

Director General of Engineering Affairs, MOH

Director General of Royal Hospital

Director General of Khoula Hospital

Director General of Medical Supplies (MOH)

Director General of Pvt. Health Est. Affairs (to kindly arrange distribution to all Pvt. Hospitals)

Hospital Director (Al Nahda Hospital)

Hospital Director (Al Massara Hospital)

The Head of Medical Services in SQU Hospital

The Head of Medical Services in Royal Oman Police

The Head of Medical Services in Ministry of Defence

The Head of Medical Services in The Diwan

The Head of Medical Services in The Sultan's Special Force

The Head of Medical Services in Internal Security Services

The Head of Medical Services in Petroleum Development of Oman

The Head of Medical Services in LNG Oman

ALL PRIVATE PHARMACIES & DRUG STORES

After Compliments,

Please find attached our Circular No 249 dated 29/12/2022 Regarding NCMDR Field Safety Corrective Action of Novocastra Liquid Mouse Monoclonal Antibody Muscle Specific Actin from (mfr: Leica Biosystems).

Copy to:

- Director, Office of H.E. The Undersecretary for Health Affairs
- Director of Medical Device Control, DGPA&DC
- Director of Pharmacovigilance & Drug Information Dept, DGPA&DC
- Director of Drug Control Department, DGPA&DC
- Director of Pharmaceutical Licensing Department, DGPA&DC
- Director of Central Quality Control Lab., DGPA&DC
- Supdt. of Central Drug Information





Circular No. 249/2022

نحن نقدم
تقدم
Moving Forward
with Confidence



05 -06-1444 H

29 -12-2022

FSCA of Novocastra Liquid Mouse Monoclonal Antibody Muscle Specific Actin from Leica Biosystems.

Source	NCMDR - National Center Medical Device Reporting- SFDA. https://ncmdr.sfda.gov.sa/Secure/CA/CAViewRecall.aspx?caid=6&rid=18400
Product	Novocastra Liquid Mouse Monoclonal Antibody Muscle Specific Actin.
Description	In-vitro diagnostics - immunological products.
Manufacturer	Leica Biosystems.
Local agent	Aston Medical Supplies.
The affected products	NCL-L-MSA-594 Lot(s) #: 6086929, 6089716, 6083632, 6080639, 6099941, 6074404, 6074748.
Reason	IFU of affected device incorrectly states a suggested dilution of 1/400 and a concentration of 243mg/L, when in fact it should read 1/200 and 135mg/L.
Action	1. Notify customers of the change in labelling only. 2. Contact the local agent for remedial action.
comments	Healthcare professionals are encouraged to report any adverse events Suspected to be associated with the above device or any other medical device to Department of Medical Device Control through the E-mail: Med-device@moh.gov.om

Dr. Mohammed Hamdan Al Rubaie
Director General



PADDC
المديرية العامة للصيدلة والرقابة الدوائية
Directorate General of Pharmaceutical
Affairs & Drug Control



ص.ب: ٣٩٣ مسقط - الرمز البريدي: 1٠٠ - هاتف: ٢٢٣٥٧١١١ - فاكس: ٢٢٣٥٨٤٨٩
P.O. Box: 393 Muscat - Postal Code: 100 - Tel: 22357111 - Fax: 22358489
dgpa_dc Email: dg-padc@moh.gov.om